Cancer/Oncology
13 drugs in this class, prescribed by 28,846 Medicare Part D providers.
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$6.71B
Total Cost
1,193,629
Claims
13
Drugs
$5,619
Avg Cost/Claim
Key Insights
- Most expensive per prescription: Iclusig at $21K/claim
- Most prescribed: Anastrozole with 626,025 claims
- This class represents 2.4% of total Medicare Part D spending
All Cancer/Oncology Drugs
| Drug | Cost | Claims |
|---|---|---|
| Lenalidomide | $2.15B | 130,834 |
| Enzalutamide | $985.0M | 72,710 |
| Ibrutinib | $875.8M | 56,368 |
| Palbociclib | $755.1M | 48,329 |
| Ruxolitinib Phosphate | $698.1M | 46,655 |
| Osimertinib Mesylate | $436.5M | 25,273 |
| Abiraterone Acetate | $345.0M | 122,643 |
| Dasatinib | $136.8M | 10,389 |
| Nilotinib Hcl | $100.9M | 6,308 |
| Ribociclib Succinate | $90.3M | 5,978 |
| Imatinib Mesylate | $85.0M | 40,908 |
| Ponatinib Hcl | $25.6M | 1,209 |
| Anastrozole | $17.4M | 626,025 |